Uğur Şahin, BioNTech CEO (Hannes P Albert/picture-alliance/dpa/AP Images)
New cancer class heats up as BioNTech buys out China partner and its PD-L1/VEGF drug
After initially promising more than $1 billion in biobucks to its partner Biotheus for a single drug, BioNTech is now buying out all of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
